Skip to main navigation

About
Science
Pipeline
Patients
Investors
News
Careers
Contact
Menu Menu

Press Releases

Press Releases
Events & Presentations
- Events
- Presentations
Corporate Governance
Financials & Filings
- SEC Filings
- Quarterly Results
Stock Information
IR Resources

Year

eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer

11.28.2023
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting

11.15.2023
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

11.13.2023
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference

11.06.2023
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia

10.24.2023
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors

09.11.2023
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

08.30.2023
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08.08.2023
eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings

06.08.2023
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

06.07.2023

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

Home
About
Science
Pipeline
Patients
Investors
News
Careers
Contact

Copyright © 2023 eFFECTOR Therapeutics, Inc. | Privacy Policy

Scroll to top